Supernus v. Zydus Lifesciences: Qelbree® ANDA Patent Battle Consolidated
Supernus Pharmaceuticals filed suit against Zydus Lifesciences Global FZE in the District of New Jersey asserting three Orange Book-listed patents covering Qelbree® viloxazine extended-release capsules. Within 180 days, the case was consolidated with actions against more than a dozen ANDA filers, signalling a major multi-front generic challenge to the branded ADHD therapy.
Three Orange Book Patents, Fourteen Defendants: Inside the Qelbree® ANDA War
Supernus Pharmaceuticals filed Case No. 2:25-cv-12188 in the District of New Jersey on 26 June 2025, asserting infringement of three Orange Book-listed patents — US9358204B2, US9603853B2, and US9662338B2 — against Zydus Lifesciences Global FZE. The patents protect Qelbree® (viloxazine extended-release capsules at 100 mg, 150 mg, and 200 mg), Supernus’s branded non-stimulant ADHD treatment, and the lawsuit was triggered by Zydus’s Abbreviated New Drug Application (ANDA) seeking FDA approval for a generic version.
The case was not dismissed but was procedurally consolidated on 23 December 2025 — 180 days after filing — pursuant to a Consolidation Order directed by the Court at the 17 December 2025 Initial Scheduling Conference. The consolidated docket groups Zydus with at least thirteen other ANDA defendants including Appco Pharma, Apotex, Aurobindo, MSN Pharmaceuticals, Macleods Pharmaceuticals, and others, all subject to the same pretrial schedule anchored to the lead action, Civil Action No. 25-12183.
The speed of consolidation — achieved before substantive pretrial motions — suggests the Court identified significant overlap in claim construction and validity questions across all defendants. Consolidation typically benefits the patent holder in resource terms but raises litigation risk if any defendant mounts a successful invalidity defence that binds the consolidated record. The public docket does not yet reveal whether any 30-month stay has been triggered or whether any defendant has sought early summary judgment.
Filing to Case Consolidated in 180 days
180 days from filing to consolidation — faster than typical ANDA Hatch-Waxman scheduling
Full party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Supernus Pharmaceuticals, Inc. | Company | Specialty pharmaceutical company — holder of US9358204B2, US9603853B2, and US9662338B2 for Qelbree®Search in Eureka ↗ |
| Defendant | ZYDUS LIFESCIENCES GLOBAL FZE | Individual | Generic pharmaceutical manufacturer (UAE-based FZE entity) — ANDA filer for viloxazine ER capsulesSearch in Eureka ↗ |
| Plaintiff counsel | Alexander Lee Callo | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | EDGAR H. HAUG | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | JONATHAN HERSTOFF | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | KAITLIN M. FARRELL | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | NICHOLAS F. GIOVE | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Richard Frank Kurz | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | William C. Baton | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | COUNSEL NOT ADMITTED TO USDC – NJ BAR | Law Firm | Representing Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Haug Partners, LLP | Law Firm | Representing Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Saul Ewing, LLP | Law Firm | Representing Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | ALEC WONG | Attorney | Counsel for ZYDUS LIFESCIENCES GLOBAL FZESearch in Eureka ↗ |
| Defendant counsel | JACOB C. BRITZ | Attorney | Counsel for ZYDUS LIFESCIENCES GLOBAL FZESearch in Eureka ↗ |
| Defendant counsel | JAMES T. PETERKA | Attorney | Counsel for ZYDUS LIFESCIENCES GLOBAL FZESearch in Eureka ↗ |
| Defendant counsel | Lauren Brophy Cooper | Attorney | Counsel for ZYDUS LIFESCIENCES GLOBAL FZESearch in Eureka ↗ |
| Defendant counsel | MICHAEL J. GAERTNER | Attorney | Counsel for ZYDUS LIFESCIENCES GLOBAL FZESearch in Eureka ↗ |
| Defendant counsel | NINA VACHHANI | Attorney | Counsel for ZYDUS LIFESCIENCES GLOBAL FZESearch in Eureka ↗ |
| Defendant counsel | Theodora T. Mccormick | Attorney | Counsel for ZYDUS LIFESCIENCES GLOBAL FZESearch in Eureka ↗ |
| Defendant counsel | Zhibin Li | Attorney | Counsel for ZYDUS LIFESCIENCES GLOBAL FZESearch in Eureka ↗ |
| Defendant law firm | Baker Donelson | Law Firm | Representing ZYDUS LIFESCIENCES GLOBAL FZESearch in Eureka ↗ |
| Defendant law firm | Buchanan Ingersoll & Rooney, PC | Law Firm | Representing ZYDUS LIFESCIENCES GLOBAL FZESearch in Eureka ↗ |
| Defendant law firm | COUNSEL NOT ADMITTED TO USDC – NJ BAR | Law Firm | Representing ZYDUS LIFESCIENCES GLOBAL FZESearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The Consolidation Order is procedural rather than substantive — no merits determination has been made on infringement or validity. The Court’s directive to consolidate fourteen ANDA actions for pretrial purposes is consistent with standard D.N.J. practice in multi-defendant Hatch-Waxman cases. It suggests the judge identified sufficient common questions of law and fact across all asserted patents and defendants. Substantive litigation on all three Orange Book patents continues under the consolidated schedule.
US9358204B2, US9603853B2 & US9662338B2 — Qelbree® Viloxazine ER Capsule Patents
US9358204B2 (App. No. 13/761757), US9603853B2 (App. No. 15/157549), and US9662338B2 (App. No. 15/172955) collectively form the Orange Book patent estate protecting Qelbree® — Supernus’s FDA-approved non-stimulant ADHD treatment. The patents cover the extended-release capsule formulations delivering viloxazine at 100 mg, 150 mg, and 200 mg doses. As Orange Book-listed patents, each triggers the automatic 30-month stay mechanism under the Hatch-Waxman Act upon an ANDA paragraph IV filing, giving Supernus a statutory window to litigate before any generic can enter the market.
Qelbree® received FDA approval in 2021 as the first new non-stimulant ADHD medication in nearly two decades, giving these formulation patents significant commercial weight. The breadth of the asserted patent family — three patents across related application numbers — suggests Supernus built layered protection around the ER delivery mechanism. For generic challengers, the consolidation of fourteen defendants means any successful invalidity argument will be litigated in a shared record, creating both efficiency and strategic risk. For branded pharma peers, the case is a template for aggressive Orange Book listing and rapid multi-defendant enforcement.
Should you run an FTO against US9358204B2, US9603853B2, and US9662338B2?
Any pharmaceutical company developing or commercialising extended-release formulations of viloxazine — or structurally analogous non-stimulant compounds targeting ADHD — should treat these three Orange Book patents as high-priority FTO targets. The active multi-defendant litigation confirms Supernus is enforcing this estate aggressively. Generic developers, contract manufacturers, and API suppliers supporting ANDA filings for viloxazine ER products face direct infringement exposure until the patents are invalidated or expire.
PatSnap Eureka’s FTO Search Agent can map the claim scope of all three patents against your formulation design, flag prosecution history estoppel, and surface prior art already cited by the fourteen co-defendants in parallel proceedings. Eureka’s litigation monitoring layer will alert your IP team the moment any IPR petition is filed against these patents at the PTAB, giving you real-time intelligence on the invalidity record being built across the consolidated case.
Run a freedom-to-operate analysis on US9358204B2 to assess your product’s exposure
Run FTO in Eureka →Similar Orange Book ANDA Patent Cases in D.N.J. — Viloxazine & ER Formulations
Multi-defendant ANDA cases asserting Orange Book formulation patents in the District of New Jersey — the busiest Hatch-Waxman jurisdiction in the US.
What the Qelbree® consolidation signals for ANDA patent strategy
A fourteen-defendant consolidated ANDA war over a non-stimulant ADHD drug raises high-stakes questions for generic and branded pharma alike.
Consolidation compresses timelines and concentrates invalidity risk
Consolidating fourteen ANDA defendants under one pretrial schedule means a single adverse claim construction or invalidity ruling could extinguish Supernus’s patent position across all challengers simultaneously. Branded pharma IP teams should stress-test all three asserted patents for shared claim vulnerabilities before the first scheduling order locks in a joint briefing calendar.
Orange Book listing strategy is under scrutiny in every ANDA wave
All three patents are Orange Book-listed, making their scope and validity directly relevant to generic market entry. Competitors and investors tracking Qelbree® market exclusivity should monitor whether any defendant files an IPR petition — a parallel PTAB challenge could accelerate the invalidity timeline independent of the district court schedule.
Supernus v ZYDUS — key questions answered
Consolidation means the Court merged Case No. 2:25-cv-12188 with related ANDA actions into a single pretrial proceeding. No merits ruling has been issued. All fourteen defendants, including Zydus Lifesciences Global FZE, are now subject to the same discovery and briefing schedule. The underlying infringement and validity disputes over US9358204B2, US9603853B2, and US9662338B2 remain live.
Supernus asserts three Orange Book-listed patents: US9358204B2 (App. No. 13/761757), US9603853B2 (App. No. 15/157549), and US9662338B2 (App. No. 15/172955). All three cover viloxazine extended-release capsule formulations for Qelbree® at 100 mg, 150 mg, and 200 mg strengths. Each patent triggers the Hatch-Waxman 30-month stay on ANDA approval upon a Paragraph IV certification.
The Consolidation Order names at least fourteen defendants: Appco Pharma LLC, Somerset Therapeutics LLC, Apotex Inc., Aurobindo Pharma Limited, Aurobindo Pharma U.S.A. Inc., Zydus Lifesciences Global FZE, Zydus Pharmaceuticals (USA) Inc., Zydus Lifesciences Limited, Creckwood Pharmaceuticals LLC, MSN Pharmaceuticals Inc., Zenara Pharma Private Limited, Biophore Pharma Inc., Macleods Pharmaceuticals Ltd., and Macleods Pharma USA Inc.
Qelbree® (viloxazine extended-release capsules) received FDA approval in 2021 as a non-stimulant treatment for ADHD. As a branded drug with Orange Book-listed patents, any generic manufacturer seeking FDA approval via an ANDA must certify to each listed patent. A Paragraph IV certification — asserting invalidity or non-infringement — triggers the right of Supernus to sue and invoke the 30-month regulatory stay preventing generic approval during litigation.
Any of the fourteen ANDA defendants could petition the USPTO Patent Trial and Appeal Board for inter partes review of US9358204B2, US9603853B2, or US9662338B2. An IPR institution would run parallel to the D.N.J. district court proceedings and, if successful, could invalidate the patents on a faster timeline. Parties and investors should monitor PTAB filings closely, as an IPR grant typically shifts settlement dynamics in the district court litigation.
PatSnap Eureka searches patents and litigation data to answer instantly.